STOCK TITAN
  1. Home
  2. News
  3. ROIV

Roivant Sciences Ltd - ROIV STOCK NEWS

Welcome to our dedicated news page for Roivant Sciences (Ticker: ROIV), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roivant Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roivant Sciences's position in the market.

News
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
Rhea-AI Summary
Roivant and Kinevant Sciences have completed enrollment in the RESOLVE-Lung Phase 2 study evaluating namilumab for chronic pulmonary sarcoidosis. Namilumab inhibits GM-CSF to target the underlying cause of the disease. The topline results are expected by the end of 2024. Sarcoidosis affects millions globally, and this study aims to provide a new treatment option for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Rhea-AI Summary
Roivant (ROIV) announces a $1.5 billion share repurchase program and positive Phase 2 study results for brepocitinib in non-infectious uveitis (NIU). The repurchase includes buying back Sumitomo Pharma's stake, reducing shares outstanding by 9%. NEPTUNE study shows promising efficacy data, with Treatment Failure rates of 29% for 45 mg and 44% for 15 mg. Brepocitinib demonstrates potential as a multi-blockbuster franchise in specialty autoimmunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
buyback
-
News
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
Rhea-AI Summary
Roivant (ROIV) reports strong financial results for Q3 2023, completes $7.1B sale of Telavant to Roche, and achieves positive clinical trial results for Batoclimab and VTAMA products. The company maintains a healthy cash position of $6.7B, supporting future growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
earnings
News
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
Rhea-AI Summary
Roivant (ROIV) will host a live conference call and webcast to report its financial results for the third quarter ended December 31, 2023, and provide a business update on February 13, 2024. The conference call details can be accessed on the Roivant website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
conferences earnings
-
News
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Rhea-AI Summary
Immunovant, Inc. (Nasdaq: IMVT) announced promising results from the initial cohort of patients in a 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease. The trial demonstrated a meaningful response rate of over 50%, with potential best-in class IgG reduction of up to 87% after 12 weeks of treatment. The primary and secondary outcome measurements of the trial are being measured at weeks 12 and 24, showing a dose response on efficacy between different regimens of batoclimab. The treatment was generally well-tolerated with no new safety signals observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
clinical trial
-
News
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
Rhea-AI Summary
Roivant (Nasdaq: ROIV) completes the acquisition of Telavant by Roche (SIX: RO, ROG; OTCQX: RHHBY) for $7.1 billion, with an upfront payment and a near-term milestone payment. Telavant holds rights to RVT-3101, a therapy for inflammatory bowel disease in the US and Japan. Roivant previously owned 75% of Telavant's shares. Roche aims to continue RVT-3101's development across multiple indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
acquisition
News
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
Rhea-AI Summary
Immunovant, Inc. (IMVT) announced initial data from the 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402, showing that four subcutaneously administered doses of 600 mg produced a mean IgG reduction similar to high dose batoclimab, with minimal changes in albumin and LDL-C, confirming the potential of IMVT-1402 as a best-in-class FcRn inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
News
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Rhea-AI Summary
Roivant (ROIV) and Priovant announce that the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 (SRI-4) at Week 52. However, Priovant plans to continue progressing the program in indications outside of Systemic Lupus Erythematosus (SLE) due to the drug’s favorable safety and tolerability profile, six other positive phase 2 studies, and active arm performance in this study. Priovant also expects to announce topline results from the Phase 2 POC study of brepocitinib in non-infectious uveitis (NIU) in the first quarter of calendar year 2024 and topline results from the Phase 3 trial in dermatomyositis (DM) in calendar year 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
clinical trial
-
News
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
Rhea-AI Summary
Roivant (ROIV) reported a definitive agreement with Roche for the sale of Telavant for $7.1B upfront and a milestone payment of $150M. IMVT-1402 SC doses achieved peak IgG reductions similar to batoclimab. VTAMA® cream generated $18.4M in net product revenue for the quarter. Cash, cash equivalents, and restricted cash were approximately $1.4B at September 30, 2023, expected to reach $7.0B with pending sale proceeds. Mayukh Sukhatme, M.D. appointed to the Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
earnings
News
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
Rhea-AI Summary
Roivant (Nasdaq: ROIV) appoints Mayukh Sukhatme, M.D., as a new member of its Board of Directors, expanding the board to eight members. Dr. Sukhatme's extensive experience in the pharmaceutical industry and his role in driving positive Phase 3 studies and FDA approvals make him a valuable addition to the board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
management
Stock ROIV logo
Roivant Sciences Ltd

Nasdaq:ROIV

ROIV Rankings

#859 Ranked by Market Cap
#290 Ranked by Stock Gains
N/A Ranked by Dividends

ROIV Stock Data

8.82B
423.13M
20.63%
62.12%
3.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
UK
London

About ROIV

roivant is a global healthcare company focused on rapidly developing innovative medicines. we believe that the key to unlocking innovation in drug discovery and drug commercialization is to reduce the time and cost of the drug development process. we solve this problem by building vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in pharma r&d; and commercialization. the goal of our model is to ensure that important medicines rapidly reach patients who suffer from serious diseases. we focus on disease areas where the magnitude of r&d; investment from industry is disproportionately low relative to societal medical needs. we also launch new vants to directly improve the process of developing and commercializing new medicines. our pipeline spans multiple therapeutic areas through partnerships with academic institutions and biopharmaceutical companies, including tak